Prostate cancer — all decisions

The Board denied service connection for a benign frontotemporal brain tumor and prostate cancer, finding that the evidence did not support a causal relationship between these conditions and the Veteran's military service.

The Board dismissed the appeal for entitlement to an earlier effective date for service connection for prostate cancer and obstructive sleep apnea due to a concurrent election of review options.

The Board denied the Veteran's claims for service connection for diabetes mellitus, type II and prostate cancer due to a lack of evidence supporting direct causation or presumptive exposure.

The Board remands the service-connection claim for prostate cancer for further development, including a VA examination to address the Veteran's claims of direct and presumptive service connection based on exposure to contaminated water at Camp LeJeune.

The Board granted eligibility for the direct payment of attorney fees based on 20 percent of past due benefits awarded in a May 2023 rating decision, but denied entitlement to additional fees.

The Board denied service connection for prostate cancer as the evidence did not support a finding that it was incurred in or caused by active service, to include exposure to herbicides and diesel/jet fuels.

The Board denied service connection for diabetes mellitus type II, hypertension, and hypothyroidism prior to August 10, 2022, but granted a 10 percent rating for painful scars of the bilateral knees.

The Board granted an effective date of January 15, 2021, for service connection for prostate cancer and related conditions.

The Board denied an initial compensable disability rating for bilateral hearing loss and remanded the service connection claims for prostate cancer, kidney cancer, cervical spine disability, thoracolumbar spine disability, right hip disability, and left hip disability.

The Board denied service connection for prostate cancer residuals and lung cancer residuals as the evidence did not show a relationship to active military service.

The Board granted service connection for prostate cancer and kidney cancer under the PACT Act, but remanded claims for erectile dysfunction, prostate cancer on a basis other than the PACT Act, and kidney cancer on a basis other than the PACT Act.

The Board remands the claims for service connection for prostate cancer and obstructive sleep apnea to schedule VA examinations and obtain medical opinions regarding their etiology, considering toxic exposure during service.

The Board granted service connection for prostate cancer, to include as due to in-service exposure to herbicide agents, resolving all reasonable doubt in the Veteran's favor.

The Board denied service connection for prostate cancer, ED, and a mental condition as they were not causally or etiologically related to the Veteran's active service.

The Board granted an initial rating of 100 percent for prostate cancer from November 1, 2023, to May 21, 2024, and denied an earlier effective date for the grant of service connection for prostate cancer. The claim for service connection for dementia was remanded.

The Veteran withdrew his appeal, and the Board dismissed all service connection claims.

The Veteran's erectile dysfunction was found to be aggravated by his service-connected prostate cancer, and an earlier effective date of July 3, 2017, for special monthly compensation based on loss of use of a creative organ is granted.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that there was no evidence of an in-service injury or event and that his prostate cancer did not have its onset during service.

The Board remands the claim for service connection for metastatic prostate cancer with nocturia due to insufficient evidence regarding exposure to toxic materials, including ionizing radiation.

The Board granted service connection for prostate cancer and remanded the claims for cardiovascular disease and hypertension for a new VA medical opinion.